RXRXRecursion Pharmaceuticals, Inc.
$3.70-42% 1Y
$3.70
$2.8452 weeks$6.68
Is the price fair?
What RXRX's price assumes
Recursion Pharmaceuticals, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 36.1× revenue.
36.1
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 2.16
Price / book · today's price, trailing year to Jun 30, 2026
- EV / sales
- 26.4
EV / sales
Details›
- Price / booktoday's price, trailing year to Jun 30, 2026
- 2.16
- EV / EBIToperating margin −992%: the multiple describes the denominator
- not meaningful
- EV / salestoday's price, trailing year to Jun 30, 2026
- 26.4
- Market capitalisation535.3 million shares, counted Jul 31, 2026
- $1.98B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
On our screens:Most shorted stocks